DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...
NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
LOS ANGELES (Reuters) - Amgen Inc dodged a bullet on Thursday when a U.S. advisory panel recommended tighter use of anemia drugs, but said the medicines should remain on the market for most cancer ...
Amgen is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety. Amgen confirmed ...
April 23, 2007 — Using actual US practice patterns and dosing, epoetin alfa (Epogen; peg-EPO therapy) effectively maintains hemoglobin (Hb) levels in hemodialysis patients, according to a presentation ...
Treatment of Nonmetastatic Rhabdomyosarcoma in Childhood and Adolescence: Third Study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89 Epoetin alfa significantly ...
Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel said Monday. Outside advisers to the Food and Drug Administration said the ...
The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results